Overview
International law firm McDermott Will & Emery assisted Claris Ventures in an EUR 6.9 million investment round in ALKemist Bio to support a TCR cellular therapy for the ultimate generation of positive ALK tumors.
Claris Ventures SGR SpA makes equity investments in early-stage biopharma companies with a clear vision and solid scientific evidence.
ALKemist is a pioneering biotech company born from the research of Professor Roberto Chiarle, dedicated to developing cellular immunotherapies for patients with ALK-positive tumors.
The McDermott team advising Claris Ventures was led by Milan-based corporate partner Ettore Scandale, supported by associate Carlo Lemmi and trainee Carlo Serranò.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
